Literature DB >> 12419581

Identification of novel mutations in the RB1 gene in Mexican patients with retinoblastoma.

Maricela Rodríguez1, Mauricio Salcedo, Marina González, Ramón Coral-Vazquez, Fabio Salamanca, Diego Arenas.   

Abstract

Retinoblastoma (RB) is a childhood tumor of the eye with an average incidence of one case in every 15,000-20,000 live births and occurs in sporadic or hereditary form. This cancer results from loss or inactivation of the RB1 gene located at 13q14.1. This gene encodes for a 110 Kd nuclear phosphoprotein (pRB) that plays a major role in cell proliferation control. Different types of mutations in the RB1 gene have been reported, but point mutations are the most common. There are no molecular studies on RB1 gene mutation in Mexican patients. In this study, 19 patients with bilateral or unilateral RB were analyzed. Genetic and cytogenetic studies were carried out. Detection of RB1 gene mutations was done using single-strand conformational polymorphism (SSCP). Five conformational polymorphisms were identified in different exons. In all cases, SSCP sequence showed new non-described mutations that produced a frameshift on the open reading frame. The identification of mutations in the RB1 gene contributes to basic knowledge of this neoplasia and permits the possibility to offer adequate genetic counseling to relatives at risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419581     DOI: 10.1016/s0165-4608(02)00577-0

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  Two new mutations and three novel polymorphisms in the RB1 gene in Ecuadorian patients.

Authors:  Paola E Leone; María Elena Vega; Paola Jervis; Angel Pestaña; Javier Alonso; César Paz-Y-Miño
Journal:  J Hum Genet       Date:  2003-11-19       Impact factor: 3.172

2.  Mutational screening of germline RB1 gene in Vietnamese patients with retinoblastoma reveals three novel mutations.

Authors:  Ha Hai Nguyen; Hoa Thi Thanh Nguyen; Nhung Phuong Vu; Quynh Thuy Le; Chau Minh Pham; Thuong Thi Huyen; Hung Manh; Hang Le Bich Pham; Ton Dang Nguyen; Hien Thi Thu Le; Hai Van Nong
Journal:  Mol Vis       Date:  2018-03-17       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.